CD33 and neoplasm: Next, we investigated genes and their associated pathways, which were steadily upregulated (Supplementary Fig. 2a) or downregulated in tumor-infiltrating CD33+ myeloid cells of CRC patients across disease stages (Stages I, II and IV) (Supplementary Fig. 2b).